V600-mutated Braf Unresectable Melanoma

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2020-05-28
Clinical Trial Update: A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF Melanoma [Phase 1]
A Phase 1b open-label dose-escalation study of PLX3397 in combination with vemurafenib in V600-mutated BRAF melanoma has been terminated; re…